دورية أكاديمية
أعرض في EDS

Manuka honey as a non-antibiotic alternative against Staphylococcus spp. and their small colony variant (SCVs) phenotypes.

التفاصيل البيبلوغرافية
العنوان: Manuka honey as a non-antibiotic alternative against Staphylococcus spp. and their small colony variant (SCVs) phenotypes.
المؤلفون: Onyango LA; Department of Biology, Trinity Western University, Langley, BC, Canada., Liang J; Department of Biology, Trinity Western University, Langley, BC, Canada.
المصدر: Frontiers in cellular and infection microbiology [Front Cell Infect Microbiol] 2024 May 28; Vol. 14, pp. 1380289. Date of Electronic Publication: 2024 May 28 (Print Publication: 2024).
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Frontiers Media SA Country of Publication: Switzerland NLM ID: 101585359 Publication Model: eCollection Cited Medium: Internet ISSN: 2235-2988 (Electronic) Linking ISSN: 22352988 NLM ISO Abbreviation: Front Cell Infect Microbiol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Lausanne : Frontiers Media SA
مواضيع طبية MeSH: Honey* , Staphylococcal Infections*/drug therapy , Staphylococcal Infections*/microbiology , Staphylococcus*/drug effects , Anti-Bacterial Agents*/pharmacology, Humans ; Phenotype ; Biofilms/drug effects ; Biofilms/growth & development ; Animals ; Leptospermum/chemistry ; Microbial Sensitivity Tests
مستخلص: The antibiotic resistance (ABR) crisis is an urgent global health priority. Staphylococci are among the problematic bacteria contributing to this emergency owing to their recalcitrance to many clinically important antibiotics. Staphylococcal pathogenesis is further complicated by the presence of small colony variants (SCVs), a bacterial subpopulation displaying atypical characteristics including retarded growth, prolific biofilm formation, heightened antibiotic tolerance, and enhanced intracellular persistence. These capabilities severely impede current chemotherapeutics, resulting in chronic infections, poor patient outcomes, and significant economic burden. Tackling ABR requires alternative measures beyond the conventional options that have dominated treatment regimens over the past 8 decades. Non-antibiotic therapies are gaining interest in this arena, including the use of honey, which despite having ancient therapeutic roots has now been reimagined as an alternative treatment beyond just traditional topical use, to include the treatment of an array of difficult-to-treat staphylococcal infections. This literature review focused on Manuka honey (MH) and its efficacy as an anti-staphylococcal treatment. We summarized the studies that have used this product and the technologies employed to study the antibacterial mechanisms that render MH a suitable agent for the management of problematic staphylococcal infections, including those involving staphylococcal SCVs. We also discussed the status of staphylococcal resistance development to MH and other factors that may impact its efficacy as an alternative therapy to help combat ABR.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2024 Onyango and Liang.)
References: Eur J Clin Microbiol Infect Dis. 2019 Aug;38(8):1449-1455. (PMID: 31144243)
PLoS One. 2013;8(2):e57679. (PMID: 23469049)
Int J Mol Sci. 2019 Mar 11;20(5):. (PMID: 30862021)
GMS Hyg Infect Control. 2020 Dec 02;15:Doc32. (PMID: 33391967)
Bioengineering (Basel). 2018 Jun 14;5(2):. (PMID: 29903998)
BMC Complement Altern Med. 2009 Sep 15;9:34. (PMID: 19754926)
Eur J Clin Microbiol Infect Dis. 2021 Nov;40(11):2249-2270. (PMID: 34296355)
Polymers (Basel). 2023 Jan 24;15(3):. (PMID: 36771889)
Front Public Health. 2021 Jun 17;9:684456. (PMID: 34222184)
Front Cell Infect Microbiol. 2014 Jul 28;4:99. (PMID: 25120957)
Microorganisms. 2023 Feb 25;11(3):. (PMID: 36985155)
Cureus. 2020 Jun 24;12(6):e8801. (PMID: 32617242)
J Craniomaxillofac Surg. 2023 Apr;51(4):252-260. (PMID: 37164834)
J Appl Microbiol. 2002;93(5):857-63. (PMID: 12392533)
Clin Microbiol Rev. 2016 Apr;29(2):401-27. (PMID: 26960941)
J Pharm Pharmacol. 1991 Dec;43(12):817-22. (PMID: 1687577)
Diagn Microbiol Infect Dis. 2016 Aug;85(4):471-6. (PMID: 27241371)
Front Nutr. 2022 Jul 28;9:957932. (PMID: 35967810)
Clin Microbiol Infect. 2009 Mar;15(3):238-44. (PMID: 19196261)
Appl Microbiol. 1971 Oct;22(4):693-9. (PMID: 5167101)
Evid Based Complement Alternat Med. 2009 Jun;6(2):165-73. (PMID: 18955301)
Iran J Basic Med Sci. 2013 Jun;16(6):731-42. (PMID: 23997898)
Int J Antimicrob Agents. 2012 Jul;40(1):88-9. (PMID: 22580029)
Iran J Microbiol. 2023 Feb;15(1):89-101. (PMID: 37069905)
J Immunol. 2000 Apr 1;164(7):3713-22. (PMID: 10725730)
Ann Clin Microbiol Antimicrob. 2014 May 12;13:19. (PMID: 24884949)
mSystems. 2020 Jun 30;5(3):. (PMID: 32606022)
Pilot Feasibility Stud. 2022 Sep 24;8(1):216. (PMID: 36153609)
Eur J Clin Microbiol Infect Dis. 2010 Jan;29(1):45-50. (PMID: 19813035)
Annu Rev Med. 1999;50:223-36. (PMID: 10073274)
J Infect Dis. 2017 Feb 1;215(3):488-490. (PMID: 27974434)
Clin Exp Optom. 2023 Jul;106(5):455-465. (PMID: 35950413)
J R Soc Med. 1989 Jul;82(7):384-5. (PMID: 2685300)
Lancet. 2022 Feb 12;399(10325):629-655. (PMID: 35065702)
Int Forum Allergy Rhinol. 2011 Sep-Oct;1(5):348-50. (PMID: 22287464)
J Arthroplasty. 2010 Sep;25(6 Suppl):103-7. (PMID: 20570103)
Nat Prod Res. 2023 Nov-Dec;37(24):4280-4289. (PMID: 36719419)
Front Cell Infect Microbiol. 2023 Oct 19;13:1219984. (PMID: 37928190)
Br J Nurs. 2019 Mar 28;28(6):S30-S35. (PMID: 30925246)
Infect Immun. 2006 Feb;74(2):1091-6. (PMID: 16428756)
J Antimicrob Chemother. 2012 Jun;67(6):1405-7. (PMID: 22382468)
Gels. 2019 Apr 18;5(2):. (PMID: 31003516)
Biomaterials. 2023 Mar;294:122015. (PMID: 36701999)
Int J Nanomedicine. 2017 Nov 10;12:8211-8225. (PMID: 29184409)
Injury. 2006 May;37 Suppl 2:S26-33. (PMID: 16651068)
Antibiotics (Basel). 2020 Nov 04;9(11):. (PMID: 33158063)
Med Microbiol Immunol. 2006 Dec;195(4):185-94. (PMID: 16596413)
J Pharm Bioallied Sci. 2019 Apr-Jun;11(2):116-126. (PMID: 31148887)
Int J Environ Res Public Health. 2020 May 21;17(10):. (PMID: 32455701)
J Pathog. 2018 Sep 20;2018:1092632. (PMID: 30327733)
PLoS One. 2013 Oct 18;8(10):e77614. (PMID: 24204894)
J Infect Dis. 1998 Apr;177(4):1023-9. (PMID: 9534977)
J Appl Microbiol. 2020 Apr;128(4):1015-1024. (PMID: 31782867)
Vet Res Commun. 2016 Dec;40(3-4):97-106. (PMID: 27255108)
Front Immunol. 2024 Feb 20;15:1354297. (PMID: 38444857)
Microbiol Insights. 2015 Sep 22;8:15-23. (PMID: 26448688)
J Clin Invest. 1954 Dec;33(12):1611-22. (PMID: 13211817)
Clin Infect Dis. 2001 May 15;32 Suppl 2:S114-32. (PMID: 11320452)
Evol Appl. 2021 Mar 10;14(5):1314-1327. (PMID: 34025770)
Antioxidants (Basel). 2023 Feb 08;12(2):. (PMID: 36829972)
J Antibiot (Tokyo). 2015 Feb;68(2):98-105. (PMID: 25160508)
Foods. 2023 Mar 04;12(5):. (PMID: 36900615)
Materials (Basel). 2023 Feb 01;16(3):. (PMID: 36770254)
PLoS One. 2012;7(9):e45600. (PMID: 23049822)
Sci Rep. 2020 Aug 11;10(1):13552. (PMID: 32782291)
J Clin Pathol. 1952 Nov;5(4):354-5. (PMID: 13011225)
Diagn Microbiol Infect Dis. 2005 Jun;52(2):113-22. (PMID: 15964499)
Eur J Clin Microbiol Infect Dis. 2009 Oct;28(10):1199-208. (PMID: 19513768)
J Med Microbiol. 2009 Aug;58(Pt 8):1067-1073. (PMID: 19528167)
J Antimicrob Chemother. 2007 May;59(5):848-53. (PMID: 17337510)
PLoS One. 2016 Dec 28;11(12):e0167780. (PMID: 28030589)
Clin Orthop Relat Res. 2021 Jul 1;479(7):1471-1481. (PMID: 33835090)
Polymers (Basel). 2020 Jun 26;12(6):. (PMID: 32604824)
Vet Microbiol. 2009 Feb 16;134(1-2):45-54. (PMID: 18986783)
J Antimicrob Chemother. 2007 Jan;59(1):43-50. (PMID: 17079243)
Nat Microbiol. 2020 Jan;5(1):141-153. (PMID: 31686028)
PLoS One. 2011 Mar 04;6(3):e17709. (PMID: 21394213)
Nat Rev Microbiol. 2023 Feb;21(2):97-111. (PMID: 36042296)
Antibiotics (Basel). 2021 Jun 15;10(6):. (PMID: 34203716)
Environ Microbiol. 2004 Jun;6(6):546-51. (PMID: 15142242)
Nat Rev Microbiol. 2009 Sep;7(9):629-41. (PMID: 19680247)
Scand J Infect Dis. 2009;41(5):341-7. (PMID: 19308800)
Int J Antimicrob Agents. 2012 Jul;40(1):43-50. (PMID: 22580031)
Appl Environ Microbiol. 2020 Oct 1;86(20):. (PMID: 32801179)
Int J Antimicrob Agents. 2011 Apr;37(4):373-6. (PMID: 21349691)
J Antimicrob Chemother. 2009 Sep;64 Suppl 1:i29-36. (PMID: 19675016)
Open Forum Infect Dis. 2020 Feb 28;7(3):ofaa072. (PMID: 32195290)
Carbohydr Res. 2012 Nov 1;361:7-11. (PMID: 22960208)
Evid Based Complement Alternat Med. 2017;2017:5413917. (PMID: 28250794)
Med Princ Pract. 2020;29(1):61-68. (PMID: 31256152)
Carbohydr Res. 2008 Mar 17;343(4):651-9. (PMID: 18194804)
J Glob Antimicrob Resist. 2014 Sep;2(3):168-172. (PMID: 27873724)
Front Microbiol. 2013 Mar 12;4:47. (PMID: 23487476)
Br J Exp Pathol. 1951 Aug;32(4):307-13. (PMID: 14886490)
Antibiotics (Basel). 2020 Oct 31;9(11):. (PMID: 33142845)
Infect Immun. 1999 Aug;67(8):3703-13. (PMID: 10417127)
Microorganisms. 2023 Jun 19;11(6):. (PMID: 37375116)
Microbiol Spectr. 2021 Sep 3;9(1):e0061421. (PMID: 34319160)
J Infect Dis. 2016 Jan 15;213(2):305-13. (PMID: 26188074)
Curr Res Microb Sci. 2022 Nov 17;3:100175. (PMID: 36518176)
Int J Clin Pract Suppl. 2000 Dec;(115):44-9. (PMID: 11219301)
J Clin Invest. 2009 Sep;119(9):2464-74. (PMID: 19729844)
Nat Rev Microbiol. 2006 Apr;4(4):295-305. (PMID: 16541137)
Future Microbiol. 2018 Jan;13:13-26. (PMID: 29226698)
J R Soc Med. 1999 Jun;92(6):283-5. (PMID: 10472280)
Nutr Res Rev. 2020 Jun;33(1):50-76. (PMID: 31791437)
Clin Microbiol Rev. 1994 Jan;7(1):117-40. (PMID: 8118787)
Curr Biol. 2001 Nov 13;11(22):1810-4. (PMID: 11719226)
J Clin Microbiol. 2003 Jan;41(1):410-3. (PMID: 12517881)
Front Cell Infect Microbiol. 2019 Oct 22;9:363. (PMID: 31696062)
Pharmaceuticals (Basel). 2023 May 18;16(5):. (PMID: 37242545)
Infect Control Hosp Epidemiol. 1999 Jun;20(6):408-11. (PMID: 10395142)
Int J Antimicrob Agents. 2000 Nov;16 Suppl 1:S3-10. (PMID: 11137402)
Antibiotics (Basel). 2020 Aug 19;9(9):. (PMID: 32825100)
J Agric Food Chem. 2014 Jul 9;62(27):6400-7. (PMID: 24941263)
Microorganisms. 2019 Aug 13;7(8):. (PMID: 31412630)
Biofilm. 2022 Feb 02;4:100068. (PMID: 35198967)
EMBO Mol Med. 2011 Mar;3(3):129-41. (PMID: 21268281)
Saudi J Biol Sci. 2019 Sep;26(6):1285-1290. (PMID: 31516359)
Clin Infect Dis. 2005 Mar 15;40(6):896-8. (PMID: 15736028)
J Hosp Infect. 1992 Sep;22(1):19-31. (PMID: 1358944)
Curr Opin Microbiol. 2003 Apr;6(2):140-5. (PMID: 12732303)
Future Med Chem. 2012 Jun;4(10):1273-306. (PMID: 22800371)
Antibiotics (Basel). 2021 May 09;10(5):. (PMID: 34065141)
Int J Food Microbiol. 2008 Sep 30;127(1-2):99-104. (PMID: 18625535)
J Agric Food Chem. 2012 Apr 4;60(13):3418-23. (PMID: 22409307)
J Antibiot (Tokyo). 2020 Jul;73(7):421-428. (PMID: 32203126)
Front Immunol. 2022 Nov 02;13:1020574. (PMID: 36405698)
Future Microbiol. 2013 Nov;8(11):1419-29. (PMID: 24199801)
P T. 2015 Apr;40(4):277-83. (PMID: 25859123)
Eur J Clin Microbiol Infect Dis. 2003 Dec;22(12):746-8. (PMID: 14605939)
J Pharm Pharmacol. 1996 Nov;48(11):1206-9. (PMID: 8961174)
Microbiol Spectr. 2019 May;7(3):. (PMID: 31198131)
Nature. 2002 Apr 18;416(6882):740-3. (PMID: 11961556)
Nat Microbiol. 2018 Oct;3(10):1175-1185. (PMID: 30177740)
PLoS One. 2019 Oct 25;14(10):e0224495. (PMID: 31652284)
J Clin Microbiol. 1999 Jun;37(6):1771-6. (PMID: 10325322)
Clin Microbiol Rev. 2014 Oct;27(4):870-926. (PMID: 25278577)
Int J Pharm. 2023 Feb 5;632:122541. (PMID: 36566824)
J Antimicrob Chemother. 2014 Mar;69(3):603-15. (PMID: 24176984)
Curr Drug Metab. 2017;18(10):881-892. (PMID: 28901255)
Carbohydr Res. 2009 May 26;344(8):1050-3. (PMID: 19368902)
Clin Otolaryngol. 2021 Jan;46(1):168-174. (PMID: 32852889)
J Appl Bacteriol. 1992 Nov;73(5):388-94. (PMID: 1447054)
Mol Microbiol. 2002 Mar;43(6):1367-78. (PMID: 11952892)
J Infect Dis. 1994 Oct;170(4):1033-7. (PMID: 7930701)
FEMS Immunol Med Microbiol. 2004 May 1;41(1):35-41. (PMID: 15094165)
Microorganisms. 2021 Apr 14;9(4):. (PMID: 33919781)
Diagn Microbiol Infect Dis. 1999 Apr;33(4):283-97. (PMID: 10212756)
J Antimicrob Chemother. 2011 Nov;66(11):2536-42. (PMID: 21903658)
IUBMB Life. 2012 Jan;64(1):48-55. (PMID: 22095907)
Mol Nutr Food Res. 2008 Apr;52(4):483-9. (PMID: 18210383)
Br J Oral Maxillofac Surg. 2008 Jan;46(1):55-6. (PMID: 17113690)
Trends Microbiol. 2012 Jul;20(7):336-42. (PMID: 22564248)
Clin Infect Dis. 2011 Feb 1;52(3):e18-55. (PMID: 21208910)
Laryngoscope. 2011 May;121(5):1104-7. (PMID: 21520131)
Sci Rep. 2020 Aug 6;10(1):13229. (PMID: 32764604)
Emerg Infect Dis. 2003 Oct;9(10):1316-8. (PMID: 14609471)
Front Microbiol. 2018 Jan 11;8:2653. (PMID: 29375518)
Front Microbiol. 2016 Apr 20;7:569. (PMID: 27148246)
J Clin Microbiol. 1978 Aug;8(2):142-7. (PMID: 701460)
Front Microbiol. 2020 Aug 19;11:2036. (PMID: 32973735)
Front Microbiol. 2015 Jan 27;5:779. (PMID: 25674077)
Antibiotics (Basel). 2020 Oct 09;9(10):. (PMID: 33050172)
J Antimicrob Chemother. 2005 Jul;56(1):228-31. (PMID: 15941774)
Rev Argent Microbiol. 2017 Jan - Mar;49(1):15-23. (PMID: 28017482)
Expert Rev Clin Pharmacol. 2017 Nov;10(11):1203-1214. (PMID: 28836870)
PLoS One. 2023 Jan 27;18(1):e0274248. (PMID: 36706112)
J Tissue Viability. 2020 May;29(2):91-99. (PMID: 32249090)
Front Microbiol. 2021 Jan 26;12:609459. (PMID: 33574807)
فهرسة مساهمة: Keywords: Manuka honey; Staphylococci; antibiotic resistance; coagulase-negative staphylococci; non-antibiotic therapy; small colony variants
المشرفين على المادة: 0 (Anti-Bacterial Agents)
تواريخ الأحداث: Date Created: 20240613 Date Completed: 20240613 Latest Revision: 20240614
رمز التحديث: 20240615
مُعرف محوري في PubMed: PMC11168119
DOI: 10.3389/fcimb.2024.1380289
PMID: 38868298
قاعدة البيانات: MEDLINE
الوصف
تدمد:2235-2988
DOI:10.3389/fcimb.2024.1380289